Editors’ Picks, March 2024: Synergy’s Impact on Resistance, New Early Detection Tools, and More
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
For most solid tumors, traditional biopsies are the gold standard for diagnosing cancer and assessing molecular characteristics that may...
With the August 2020 U.S. Food and Drug Administration approvals of the Guardant 360 CDx and FoundationOne Liquid CDx...
Circulating tumor DNA (ctDNA) was first detected over 30 years ago, but its potential uses for cancer diagnosis and...
Liquid biopsies, noninvasive tests performed on biofluids to detect genetic alterations in tumors, are a recent revolution in the...
In the span of a decade, the idea that tumor-derived molecules circulating in the bloodstream and other body fluids...
Cancer is the second leading cause of death globally, accounting for nearly 10 million deaths each year. Late-stage diagnosis is a major contributor of cancer-related mortality, as...
The second day of the AACR Virtual Annual Meeting II began with a clinical trials plenary session. Two of the session’s presentations, which focused on immunotherapy clinical...
Biopsies have been an integral part of cancer care for decades. In undiagnosed patients, oncologists can examine suspicious tissues...
As the 2018 Annual Meeting of the American Association for Cancer Research unfolded yesterday morning, the excitement among the...
On June 1, the U.S. Food and Drug Administration (FDA) approved a liquid biopsy test, a companion diagnostic test...